Moonlake Immunotherapeutics (MLTX) Stock Price & Analysis
Moonlake Immunotherapeutics (MLTX) fell 1.76% to USD 19.02 as of July 25, 2026 at 15:44 UTC, according to Nexqual real-time market data.
MLTX last closed at USD 19.36; the session ranged USD 18.82–19.6 on volume of 650,755 shares. Market capitalization is $1.59B, with a 52-week range of USD 5.95–62.75 (NCM). Source: Nexqual, July 25, 2026 at 15:44 UTC.
Key Statistics (as of July 25, 2026 at 15:44 UTC)
| Price | USD 19.02 |
|---|---|
| Change | ▼ 1.76% (down) |
| Previous Close | USD 19.36 |
| Open | USD 19.48 |
| Day Range | USD 18.82 – 19.6 |
| 52-Week Range | USD 5.95 – 62.75 |
| Volume | 650,755 shares |
| Market Cap | $1.59B |
| Exchange | NCM |
Technical Analysis (MLTX)
Nexqual's technical model rates MLTX "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.41 (neutral) |
| vs SMA50 | Above (USD 18.93) |
| MACD | 0.06 (positive) |
Analyst Ratings (MLTX)
Wall Street analysts rate MLTX "Buy" based on 13 analysts, with a mean price target of USD 28 (range USD 6–46), per Nexqual as of July 25, 2026 at 15:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 28 |
| High Target | USD 46 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 11 / 2 / 2 |
Earnings (MLTX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.9 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.98 vs est -0.92 ▼ miss |
| 2025-12-31 | USD -0.92 vs est -0.94 ▲ beat |
| 2025-09-30 | USD -1.1 vs est -0.92 ▼ miss |
| 2025-06-30 | USD -0.87 vs est -0.76 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Financials & Fundamentals (MLTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -77.85% |
| Debt / Equity | 39.68 |
| Current Ratio | 8.6 |
| Total Cash | $357.92M |
| Total Debt | $100.80M |
| Free Cash Flow | $-135.94M |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Financial Health Score (MLTX)
Nexqual rates Moonlake Immunotherapeutics's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $358M cash vs $101M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$224M |
| Efficiency | Critical — ROE -78%, ROA -36.7% |
Ownership (MLTX)
| Insider Ownership | +8.42% |
|---|---|
| Institutional Ownership | +78.70% |
| Shares Outstanding | 83.56M |
| Float | 43.69M |
| Short % of Float | +10.52% |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
Leadership (MLTX)
Moonlake Immunotherapeutics is led by Jorge Santos da Silva (age 48), Co-Founder, Interim Chair of the Board & CEO, per Nexqual as of July 25, 2026 at 15:44 UTC.
| Co-Founder, Interim Chair of the Board & CEO | Jorge Santos da Silva (age 48) |
|---|---|
| Co-Founder & Chief Scientific Officer | Kristian Reich (age 59) |
| Chief Financial Officer | Matthias Bodenstedt (age 37) |
| Director of Investor Relations & External Communications | Carla Bretes |
| Associate Vice-President of Legal & Compliance | Joana Cortez |
Major Backers & Investors (MLTX)
Notable institutional backers of Moonlake Immunotherapeutics include BVF Inc., Deep Track Capital, Lp, Cormorant Asset Management, LP, according to Nexqual as of July 25, 2026 at 15:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 21.74% |
| Deep Track Capital, Lp | 8.71% |
| Cormorant Asset Management, LP | 6.09% |
| Janus Henderson Group PLC | 4.69% |
| Shaw D.E. & Co., Inc. | 3.25% |
| MPM Bioimpact LLC | 2.46% |
| Weiss Asset Management Lp | 2.32% |
| Logos Global Management LP | 2.04% |
Source: Nexqual, July 25, 2026 at 15:44 UTC.
From Moonlake Immunotherapeutics's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property As of December 31, 2025, we have the exclusive license to a patent family directed to Il-17 Nanobodies, including SLK, and methods of making and using the same derived from International Patent Application PCT/EP2012/058313, published as WO 2012/156219, entitled "Amino Acid Sequences Directed Against IL-17A, IL-17F and/or IL17-A/F and Polypeptides Comprising the Same".
- In November 2025, we were granted a Type B meeting with the FDA to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application ("BLA") and in January 2026, we announced positive feedback from this interaction, confirming that we may establish substantial evidence of effectiveness ("SEE") without additional clinical trials in HS.
- The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
Partnerships
- The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement On April 29, 2021, we entered into a license agreement with MHKDG (the "License Agreement").
- Effective July 1, 2021, we entered into a contract manufacturing agreement with Richter Biologics with respect to the manufacture of SLK.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMVT | Immunovant, Inc. | USD 39.41 | ▲ 0.92% |
| NUVL | Nuvalent, Inc. | USD 123.96 | ▲ 0% |
| VERA | Vera Therapeutics, Inc. | USD 35.45 | ▼ 1.68% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| JANX | Janux Therapeutics, Inc. | USD 15.33 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:44 UTC. This page is informational and not investment advice.